Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Devices

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Revenue projections:

Revenue projections for ABT
Revenue projections for ABT

Revenues for ABT are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 15.838317
debtToEquity 26.787000
earningsGrowth -0.197000
revenueGrowth 0.078000
grossMargins 0.564650
operatingMargins 0.164990
trailingEps 3.570000
forwardEps 6.061250

ABT's Forward PE being in a good range suggests that its stock price is aligned well with earnings. The stock is not considered overpriced, offering room for future growth, which makes it an appealing investment opportunity with the potential for value appreciation.
Abbott Laboratories's low Debt-to-Equity ratio highlights its minimal reliance on debt, showing that the company is not over-leveraged. This contributes to lower financial risk and greater stability, giving Abbott Laboratories a stronger position in managing its financial obligations.
Abbott Laboratories's low earnings and revenue growth suggest shrinking profits are likely. This could reflect broader financial struggles, signaling that the company might face difficulties in sustaining its profitability.
Abbott Laboratories's negative gross and operating margins suggest that the company is struggling to cover its production and operating costs, leading to losses. This reflects a weakened financial state and potential difficulties in sustaining profitability.
ABT's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that ABT is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for ABT
Price projections for ABT

ABT's price projections have been steadily revised down, pointing to declining confidence in the company's outlook. This suggests that analysts are becoming more conservative in their expectations for ABT's future performance.

Insider Transactions:

Insider Transactions for ABT
Insider Transactions for ABT


6 transactions were made to sell ABT shares, with market price of 130.7600008646647.2 purchases of ABT stock were recorded, with market price of 107.80999755859375 per share.The insider transaction records do not exhibit a strong trend, leaving the company’s future direction unclear based on this data alone.

Recommendation changes over time:

Recommendations trend for ABT
Recommendations trend for ABT


The recent buy bias from analysts suggests ABT is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, ABT appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.